loading page

ARHGAP18/SENEX enhances apoptosis resistance of B-cell non-Hodgkin lymphoma via inhibiting CDK4/6 to promote cellular senescence
  • +3
  • Jiyu Wang,
  • Liuying Yi,
  • Keke Huang,
  • Wang Yangyang,
  • Huiping Wang,
  • Zhimin Zhai
Jiyu Wang
Second Affiliated Hospital of Anhui Medical University
Author Profile
Liuying Yi
Second Affiliated Hospital of Anhui Medical University
Author Profile
Keke Huang
Second Affiliated Hospital of Anhui Medical University
Author Profile
Wang Yangyang
Second Affiliated Hospital of Anhui Medical University
Author Profile
Huiping Wang
Second Affiliated Hospital of Anhui Medical University
Author Profile
Zhimin Zhai
Second Affiliated Hospital of Anhui Medical University

Corresponding Author:[email protected]

Author Profile

Abstract

Background: Resistance to existing therapies is currently the main reason for treatment failure in refractory/relapsed B-NHL patients, and therapy-induced senescence (TIS) is one of the important mechanisms of tumor drug resistance. Methods: Raji cells were transfected with the human SENEX shRNA recombinant lentiviral vector (Si-SENEX) and the empty vector negative (NC) to construct a stable transfection cell line with knockdown of SENEX. Effect of SENEX-silencing on B-NHL-TIS formation, cell function and cell cycle-related pathways was analyzed. We generated TIS model (using doxorubicin (dox)-inducible senescent B-NHL cells) combined with the specific CDK4/6 inhibitor Palbociclib (PAL) to observe that blocking CDK4/6 effects on TIS formation. In addition, expression levels of SENEX of 21 B-NHL patients and 8 healthy controls were tested by qRT-PCR, and the correlation between its expression and clinical indicators of patients was analyzed. Results: Downregulation of SENEX expression promotes G1-S phase transition and inhibits TIS formation in B-NHL cells to reduce the apoptosis resistance of B-NHL cells against chemotherapeutic drug DOX. Blockade of CDK4/6 promotes the DOX-induced G1 phase arrest to enhance TIS formation in B-NHL cells which can reverse the regulatory effect of silencing SENEX on B-NHL cell cycle regulation and senescence. Expression levels of SENEX in B-NHL patients were significantly increased compared to healthy controls, and Elevated expression levels of SENEX were associated with poor prognosis of B-NHL patients. Conclusions: ARHGAP18/SENEX enhances apoptosis resistance of B-NHL via inhibiting CDK4/6 to prevent G1-S phase transition and promote TIS.